As of 2025-11-08, the EV/EBITDA ratio of Chinook Therapeutics Inc (KDNY) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KDNY's latest enterprise value is 2,773.05 mil USD. KDNY's TTM EBITDA according to its financial statements is -233.23 mil USD. Dividing these 2 quantities gives us the above KDNY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.0x - 15.5x | 15.3x |
| Forward P/E multiples | 18.5x - 34.0x | 21.6x |
| Fair Price | (58.25) - (48.58) | (58.16) |
| Upside | -244.2% - -220.3% | -244.0% |
| Date | EV/EBITDA |